We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aphton has announced that its Phase III study of Insegia in combination with
chemotherapy did not meet its primary efficacy endpoint of improving overall
survival in patients with pancreatic cancer.
Integrated systems biology company Icoria has been granted a U.S. patent titled,
"Methods for the Identification of Inhibitors of Asparagine Synthase
as Antibiotics," covering the discovery of a novel gene target for antibiotic
development in a biochemical pathway by which fungi produce asparagine, a
nutrient necessary for fungal growth.
Xenova Group has announced that, Sosei, its licensee for the Japanese market,
has been granted orphan-drug status for the use of TransMID in the treatment
of glioma (a type of brain cancer) by the Ministry of Health, Labour and Welfare
(MHLW) in Japan.
A large, multisite trial designed to examine the safety and preliminary effectiveness
of two candidate topical microbicides to prevent HIV infection has opened
to volunteer enrollment.
ViroPharma has announced that dosing has begun in the Phase I clinical trial
for HCV-796, a novel polymerase inhibitor being developed as a potential new
product to treat hepatitis C.
Renovis has initiated a Phase Ia clinical trial for REN-850, an investigational
oral small molecule that is being targeted for the treatment of multiple sclerosis
(MS).
Depomed has initiated a Phase II clinical trial to evaluate the safety and efficacy
of its Gabapentin extended-release (ER) tablets to treat patients with postherpetic
neuralgia, a long-lasting pain condition associated with nerve damage from herpes
zoster, or shingles, infection.
Xcyte Therapies has presented results from two clinical trials of Xcellerated
T Cells, including data from a Phase I/II study of Xcellerated T Cells after
autologous peripheral blood stem-cell transplantation in patients with multiple
myeloma, and preliminary results from a Phase II study of Xcellerated T Cells
in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL).
Encysive Pharmaceuticals has announced topline results from the company's multicenter,
pivotal Phase III STRIDE-2 (Sitaxsentan To Relieve ImpaireD Exercise) trial
to evaluate the safety and efficacy of Thelin in patients with pulmonary arterial
hypertension (PAH).